Aclarion (ACON)

Nociscan is designed to complement conventional MRI and clinical assessment rather than replace physician judgment. Standard imaging can show structural changes in the spine, but many patients have disc degeneration that is not necessarily painful. By applying Aclarion’s proprietary biomarker analysis to spectroscopy data, the platform produces reports intended to support treatment planning, including decisions around spine surgery and other interventions. This gives the company a niche at the intersection of radiology, orthopedics, neurosurgery and digital health.

Aclarion currently derives revenue from delivering Nociscan reports to medical professionals, with substantially all sales coming from customers in the United States. Its business model depends on physician adoption, integration into clinical workflows, patient access to appropriate imaging, evidence generation and reimbursement development. For investors, ACON represents an early-stage medical technology company seeking to commercialize a specialized diagnostic service in a large but complex market. Its distinctive proposition is the use of noninvasive spectroscopy-based data to improve confidence in diagnosing disc-related back pain.